8GTI image
Entry Detail
PDB ID:
8GTI
Title:
Corticotropin-releasing hormone receptor 1(CRF1R) bound with BMK-C205 by XFEL
Biological Source:
PDB Version:
Deposition Date:
2022-09-08
Release Date:
2023-09-13
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Isoform CRF-R2 of Corticotropin-releasing factor receptor 1
Mutations:V120A, L144A, W156A, S160A, K228A, F260A, I277A, Y309A, F330A, S349A, Y363A
Chain IDs:A
Chain Length:284
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Endolysin
Mutations:C1052S, C1095S
Chain IDs:B
Chain Length:160
Number of Molecules:1
Biological Source:Enterobacteria phage T6
Primary Citation
Structure-based drug discovery of a corticotropin-releasing hormone receptor 1 antagonist using an X-ray free-electron laser.
Exp.Mol.Med. 55 2039 2050 (2023)
PMID: 37653040 DOI: 10.1038/s12276-023-01082-1

Abstact

Thus far, attempts to develop drugs that target corticotropin-releasing hormone receptor 1 (CRF1R), a drug target in stress-related therapy, have been unsuccessful. Studies have focused on using high-resolution G protein-coupled receptor (GPCR) structures to develop drugs. X-ray free-electron lasers (XFELs), which prevent radiation damage and provide access to high-resolution compositions, have helped accelerate GPCR structural studies. We elucidated the crystal structure of CRF1R complexed with a BMK-I-152 antagonist at 2.75 Å using fixed-target serial femtosecond crystallography. The results revealed that two unique hydrogen bonds are present in the hydrogen bond network, the stalk region forms an alpha helix and the hydrophobic network contains an antagonist binding site. We then developed two antagonists-BMK-C203 and BMK-C205-and determined the CRF1R/BMK-C203 and CRF1R/BMK-C205 complex structures at 2.6 and 2.2 Å, respectively. BMK-C205 exerted significant antidepressant effects in mice and, thus, may be utilized to effectively identify structure-based drugs against CRF1R.

Legend

Protein

Chemical

Disease

Primary Citation of related structures